388 related articles for article (PubMed ID: 22068036)
1. EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR.
Wang C; Liu Z; Woo CW; Li Z; Wang L; Wei JS; Marquez VE; Bates SE; Jin Q; Khan J; Ge K; Thiele CJ
Cancer Res; 2012 Jan; 72(1):315-24. PubMed ID: 22068036
[TBL] [Abstract][Full Text] [Related]
2. The role of EZH2 and DNA methylation in the silencing of the tumour suppressor RUNX3 in colorectal cancer.
Kodach LL; Jacobs RJ; Heijmans J; van Noesel CJ; Langers AM; Verspaget HW; Hommes DW; Offerhaus GJ; van den Brink GR; Hardwick JC
Carcinogenesis; 2010 Sep; 31(9):1567-75. PubMed ID: 20631058
[TBL] [Abstract][Full Text] [Related]
3. CASZ1, a candidate tumor-suppressor gene, suppresses neuroblastoma tumor growth through reprogramming gene expression.
Liu Z; Yang X; Li Z; McMahon C; Sizer C; Barenboim-Stapleton L; Bliskovsky V; Mock B; Ried T; London WB; Maris J; Khan J; Thiele CJ
Cell Death Differ; 2011 Jul; 18(7):1174-83. PubMed ID: 21252912
[TBL] [Abstract][Full Text] [Related]
4. Quantitative nuclear proteomics identifies that miR-137-mediated EZH2 reduction regulates resveratrol-induced apoptosis of neuroblastoma cells.
Ren X; Bai X; Zhang X; Li Z; Tang L; Zhao X; Li Z; Ren Y; Wei S; Wang Q; Liu C; Ji J
Mol Cell Proteomics; 2015 Feb; 14(2):316-28. PubMed ID: 25505154
[TBL] [Abstract][Full Text] [Related]
5. Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation.
Fujii S; Ito K; Ito Y; Ochiai A
J Biol Chem; 2008 Jun; 283(25):17324-32. PubMed ID: 18430739
[TBL] [Abstract][Full Text] [Related]
6. Combinatorial pharmacologic approaches target EZH2-mediated gene repression in breast cancer cells.
Sun F; Chan E; Wu Z; Yang X; Marquez VE; Yu Q
Mol Cancer Ther; 2009 Dec; 8(12):3191-202. PubMed ID: 19934278
[TBL] [Abstract][Full Text] [Related]
7. EZH2 regulates neuroblastoma cell differentiation via NTRK1 promoter epigenetic modifications.
Li Z; Takenobu H; Setyawati AN; Akita N; Haruta M; Satoh S; Shinno Y; Chikaraishi K; Mukae K; Akter J; Sugino RP; Nakazawa A; Nakagawara A; Aburatani H; Ohira M; Kamijo T
Oncogene; 2018 May; 37(20):2714-2727. PubMed ID: 29507419
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic maintenance of stemness and malignancy in peripheral neuroectodermal tumors by EZH2.
Burdach S; Plehm S; Unland R; Dirksen U; Borkhardt A; Staege MS; Müller-Tidow C; Richter GH
Cell Cycle; 2009 Jul; 8(13):1991-6. PubMed ID: 19502792
[TBL] [Abstract][Full Text] [Related]
9. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor microRNAs to promote liver cancer metastasis.
Au SL; Wong CC; Lee JM; Fan DN; Tsang FH; Ng IO; Wong CM
Hepatology; 2012 Aug; 56(2):622-31. PubMed ID: 22370893
[TBL] [Abstract][Full Text] [Related]
10. Physical interaction between MYCN oncogene and polycomb repressive complex 2 (PRC2) in neuroblastoma: functional and therapeutic implications.
Corvetta D; Chayka O; Gherardi S; D'Acunto CW; Cantilena S; Valli E; Piotrowska I; Perini G; Sala A
J Biol Chem; 2013 Mar; 288(12):8332-8341. PubMed ID: 23362253
[TBL] [Abstract][Full Text] [Related]
11. CASZ1 inhibits cell cycle progression in neuroblastoma by restoring pRb activity.
Liu Z; Rader J; He S; Phung T; Thiele CJ
Cell Cycle; 2013 Jul; 12(14):2210-8. PubMed ID: 23892435
[TBL] [Abstract][Full Text] [Related]
12. EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation.
Richter GH; Plehm S; Fasan A; Rössler S; Unland R; Bennani-Baiti IM; Hotfilder M; Löwel D; von Luettichau I; Mossbrugger I; Quintanilla-Martinez L; Kovar H; Staege MS; Müller-Tidow C; Burdach S
Proc Natl Acad Sci U S A; 2009 Mar; 106(13):5324-9. PubMed ID: 19289832
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic repression of SATB1 by polycomb group protein EZH2 in epithelial cells.
Lei L; Lu L; Xiang L; Xue-song W; De-pei L; Chih-chuan L
Chin Med Sci J; 2010 Dec; 25(4):199-205. PubMed ID: 21232178
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells.
Fiskus W; Pranpat M; Balasis M; Herger B; Rao R; Chinnaiyan A; Atadja P; Bhalla K
Mol Cancer Ther; 2006 Dec; 5(12):3096-104. PubMed ID: 17172412
[TBL] [Abstract][Full Text] [Related]
15. Downregulation of TrkB Expression and Signaling by Valproic Acid and Other Histone Deacetylase Inhibitors.
Dedoni S; Marras L; Olianas MC; Ingianni A; Onali P
J Pharmacol Exp Ther; 2019 Sep; 370(3):490-503. PubMed ID: 31308194
[TBL] [Abstract][Full Text] [Related]
16. Valproic acid upregulates the expression of the p75NTR/sortilin receptor complex to induce neuronal apoptosis.
Dedoni S; Marras L; Olianas MC; Ingianni A; Onali P
Apoptosis; 2020 Oct; 25(9-10):697-714. PubMed ID: 32712736
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of the histone methyltransferase EZH2 contributes to the epigenetic programming of decidualizing human endometrial stromal cells.
Grimaldi G; Christian M; Steel JH; Henriet P; Poutanen M; Brosens JJ
Mol Endocrinol; 2011 Nov; 25(11):1892-903. PubMed ID: 21903722
[TBL] [Abstract][Full Text] [Related]
18. EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis.
Velichutina I; Shaknovich R; Geng H; Johnson NA; Gascoyne RD; Melnick AM; Elemento O
Blood; 2010 Dec; 116(24):5247-55. PubMed ID: 20736451
[TBL] [Abstract][Full Text] [Related]
19. Polycomb repressive complex 2 regulates normal development of the mouse heart.
He A; Ma Q; Cao J; von Gise A; Zhou P; Xie H; Zhang B; Hsing M; Christodoulou DC; Cahan P; Daley GQ; Kong SW; Orkin SH; Seidman CE; Seidman JG; Pu WT
Circ Res; 2012 Feb; 110(3):406-15. PubMed ID: 22158708
[TBL] [Abstract][Full Text] [Related]
20. Polycomb protein EZH2 regulates tumor invasion via the transcriptional repression of the metastasis suppressor RKIP in breast and prostate cancer.
Ren G; Baritaki S; Marathe H; Feng J; Park S; Beach S; Bazeley PS; Beshir AB; Fenteany G; Mehra R; Daignault S; Al-Mulla F; Keller E; Bonavida B; de la Serna I; Yeung KC
Cancer Res; 2012 Jun; 72(12):3091-104. PubMed ID: 22505648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
